Clinical Trial Update: Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial SHAPER investigates losartan with hypofractionated radiotherapy after chemotherapy for Borderline Resectable or Locally Advanced Unresect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Losartan (losartan)

Snippet

Sponsor: University of Utah | Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING